HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

In brief

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.

Key facts

Study ID
NCT04153149
Run by
Alnylam Pharmaceuticals
People needed
655
Starts
2019-11-26
Expected to finish
2026-12-02
Last updated by the study team
2026-01-12

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.